00:22 , Mar 5, 2019 |  BC Extra  |  Company News

Lilly offers cheaper insulin, pressuring competitors

Lilly will offer a new, lower cost insulin that is substitutable for Humalog at pharmacies. While at least one patient group says it's not enough, the move puts pressure on the pharma’s competitors. Months of...
20:07 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Cocrystal reports SVR12 rate of 67% for CC-31244 regimen

Cocrystal Pharma Inc. (NASDAQ:COCP) reported preliminary data from an open-label, U.S. Phase IIa trial showing that eight of 12 (67%) evaluable patients with treatment-naïve HCV genotype 1 infection who received 400 mg oral CC-31244 plus...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:38 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

China approves Descovy, Harvoni, Hemlibra

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche...
20:34 , Dec 4, 2018 |  BC Extra  |  Company News

China approves Descovy, Harvoni, Hemlibra

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche...
00:25 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Epclusa, Harvoni first alternatives on Express Scripts' new formulary

Express Scripts Holding Co. (NASDAQ:ESRX) introduced a new formulary Tuesday to help lower out-of-pocket costs and reduce dependence on rebated brand products by including authorized alternative medicines with lower list prices. HCV drugs Epclusa sofosbuvir/velpatasvir...
23:10 , Oct 26, 2018 |  BC Extra  |  Politics & Policy

China essential drug list includes newly approved HCV therapy

China released its updated essential drug list , reflecting over 100 newly added drugs across multiple categories, including cancer and pediatric drugs. Cancer drugs Iressa gefitinib, MabThera rituximab, Gleevac imatinib and Herceptin trastuzumab were among...
18:44 , Sep 28, 2018 |  BC Week In Review  |  Company News

Gilead targets Medicaid with launch of HCV generics

Gilead Sciences Inc. (NASDAQ:GILD) hopes a plan to launch authorized generics of two HCV drugs will lower out-of-pocket costs for patients and increase its share in the Medicaid population. But the head of Medicaid Health...
23:13 , Sep 24, 2018 |  BC Extra  |  Company News

Gilead targets Medicaid with launch of HCV generics

Gilead Sciences Inc. (NASDAQ:GILD) hopes a plan to launch authorized generics of two HCV drugs will lower out-of-pocket costs for patients and increase its share in the Medicaid population. But the head of Medicaid Health...
22:24 , Sep 5, 2018 |  BC Extra  |  Politics & Policy

China expands essential drugs list

The China State Council outlined measures to improve the country's essential drugs list, including the addition of 187 Chinese and Western medicines. The news was announced during an Aug. 30 executive meeting. The council, which...